Trial Profile
A single-center, randomized, clinical study of a single dose of peg-rhG-CSF compared with daily rhG-CSF for supporting neutrophil recovery in acute myeloid leukemia patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jun 2019
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Filgrastim
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 03 Jun 2019 Primary endpoint (Days of neutrophil recover) has not been met, according to the results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
- 03 Jun 2019 Status changed from not yet recruiting to completed, according to the results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)
- 03 Jun 2019 Results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019)